MX2024005945A - Polipeptidos que se unen al componente del complemento c5 o albumina serica y proteinas de fusion de los mismos. - Google Patents

Polipeptidos que se unen al componente del complemento c5 o albumina serica y proteinas de fusion de los mismos.

Info

Publication number
MX2024005945A
MX2024005945A MX2024005945A MX2024005945A MX2024005945A MX 2024005945 A MX2024005945 A MX 2024005945A MX 2024005945 A MX2024005945 A MX 2024005945A MX 2024005945 A MX2024005945 A MX 2024005945A MX 2024005945 A MX2024005945 A MX 2024005945A
Authority
MX
Mexico
Prior art keywords
fusion proteins
engineered polypeptides
polypeptides
serum albumin
complement component
Prior art date
Application number
MX2024005945A
Other languages
English (en)
Spanish (es)
Inventor
Douglas L Sheridan
Paul P Tamburini
Bridget Puffer
Julian Chandler
Nimish Gera
Siddharth Jindal
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of MX2024005945A publication Critical patent/MX2024005945A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MX2024005945A 2017-07-11 2020-01-08 Polipeptidos que se unen al componente del complemento c5 o albumina serica y proteinas de fusion de los mismos. MX2024005945A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762531215P 2017-07-11 2017-07-11

Publications (1)

Publication Number Publication Date
MX2024005945A true MX2024005945A (es) 2024-06-11

Family

ID=63036501

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2024005945A MX2024005945A (es) 2017-07-11 2020-01-08 Polipeptidos que se unen al componente del complemento c5 o albumina serica y proteinas de fusion de los mismos.
MX2024005946A MX2024005946A (es) 2017-07-11 2020-01-08 Polipeptidos que se unen al componente del complemento c5 o albumina serica y proteinas de fusion de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024005946A MX2024005946A (es) 2017-07-11 2020-01-08 Polipeptidos que se unen al componente del complemento c5 o albumina serica y proteinas de fusion de los mismos.

Country Status (12)

Country Link
US (3) US11498960B2 (cg-RX-API-DMAC7.html)
EP (1) EP3625265A1 (cg-RX-API-DMAC7.html)
JP (3) JP7684803B2 (cg-RX-API-DMAC7.html)
KR (3) KR20250099285A (cg-RX-API-DMAC7.html)
CN (3) CN117327188A (cg-RX-API-DMAC7.html)
AU (3) AU2018301412B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019028269A2 (cg-RX-API-DMAC7.html)
CA (1) CA3067247A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020000369A2 (cg-RX-API-DMAC7.html)
IL (3) IL271920B2 (cg-RX-API-DMAC7.html)
MX (2) MX2024005945A (cg-RX-API-DMAC7.html)
WO (1) WO2019014360A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL271920B2 (en) 2017-07-11 2024-03-01 Alexion Pharma Inc Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
US20210388070A1 (en) * 2018-10-30 2021-12-16 Alexion Pharmaceuticals, Inc. Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
EP3956344A1 (en) * 2019-04-16 2022-02-23 University of Washington Amantadine binding protein
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
US12447173B2 (en) 2019-12-26 2025-10-21 Eisai R&D Management Co., Ltd. Pharmaceutical composition containing double-stranded ribonucleic acid inhibiting expression of complement C5
JP7343618B2 (ja) 2020-01-17 2023-09-12 オリンパス株式会社 発光装置、および駆動装置
US20230416344A1 (en) 2020-04-16 2023-12-28 Alexion Pharmaceuticals, Inc. Methods for treating a complement mediated disorder caused by viruses
US20230357442A1 (en) * 2020-10-05 2023-11-09 Alexion Pharmaceuticals, Inc. Methods of treating dermatomyositis
TW202417490A (zh) * 2022-08-31 2024-05-01 美商艾力克森製藥公司 用於治療鐮狀細胞病的融合多肽之劑量及投與
CN116731149B (zh) * 2023-06-07 2024-02-27 华中农业大学 草鱼补体活化分子碳末端肽C5a-CP及应用
CN119241699B (zh) * 2024-09-24 2025-11-28 广州康盛生物科技股份有限公司 一种抗人补体c5的单域抗体及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ATE374248T1 (de) 1996-06-27 2007-10-15 Vlaams Interuniv Inst Biotech Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren
CN1203178C (zh) 1997-10-27 2005-05-25 尤尼利弗公司 多价抗原结合蛋白
CA2921260A1 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1355919B1 (en) * 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
AU2003286002B2 (en) * 2002-11-08 2011-06-16 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CA2512545C (en) 2003-01-10 2015-06-30 Karen Silence Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf)
AU2012254935B2 (en) * 2004-02-12 2014-05-29 Archemix Llc Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders
JP2008500830A (ja) * 2004-06-01 2008-01-17 ドマンティス リミテッド 増加した血清半減期を有する二重特異性融合抗体
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
CN100368022C (zh) 2005-09-20 2008-02-13 中国人民解放军第二军医大学 双重靶向抗肝纤维化药物载体拟糖蛋白纳米粒及其制法
KR101030612B1 (ko) * 2005-10-21 2011-04-20 에프. 호프만-라 로슈 아게 폴리펩타이드의 재조합 발현 방법
NZ567483A (en) 2005-11-04 2012-04-27 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
US8435512B2 (en) 2008-03-03 2013-05-07 Novelmed Therapeutics, Inc. Anti-properdin antibodies
HUE026179T2 (en) * 2008-08-05 2016-05-30 Novartis Ag Preparations and methods for antibodies against complement C5 protein
CN102597005A (zh) 2009-06-23 2012-07-18 阿雷克森制药公司 与补体蛋白质结合的双特异性抗体
EP3009455A1 (en) 2009-09-16 2016-04-20 Immunomedics Inc. Class i anti-cea antibodies and uses thereof
EP2507262A1 (en) 2009-11-30 2012-10-10 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
EP2531523A1 (en) * 2010-02-05 2012-12-12 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
CN103003302B (zh) 2010-03-10 2015-09-30 诺沃姆德治疗公司 人源化和嵌合抗-备解素抗体
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
CN110437320B (zh) 2010-07-09 2023-10-20 阿菲博迪公司 多肽
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
AU2012279288B2 (en) 2011-07-01 2017-07-20 The Trustees Of The University Of Pennsylvania Anti-properdin antibodies and uses thereof
CA2859493A1 (en) 2011-12-21 2013-06-27 Novartis Ag Compositions and methods for antibodies targeting factor p
CN104114187A (zh) 2011-12-28 2014-10-22 诺沃姆德治疗公司 去糖基化的人类抗体、其融合蛋白质及用途
EP4616914A3 (en) 2012-02-20 2025-11-19 IPC Research, LLC Polypeptides binding to human complement c5
JP2015532303A (ja) 2012-10-04 2015-11-09 ノベルメド セラピューティクス，インコーポレーテッド 溶血性疾患を治療するための補体第２経路特異的抗体
KR20160068744A (ko) 2013-08-28 2016-06-15 애피바디 에이비 돌연변이된 스캐폴드를 갖는 결합 폴리펩티드
KR102446636B1 (ko) 2013-08-28 2022-09-23 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 안정한 폴리펩티드
NZ711451A (en) * 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
WO2018140956A1 (en) 2017-01-30 2018-08-02 Alexion Pharmaceuticals, Inc. Monovalent anti-properdin antibodies and antibody fragments
IL271920B2 (en) 2017-07-11 2024-03-01 Alexion Pharma Inc Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof

Also Published As

Publication number Publication date
IL271920A (en) 2020-02-27
IL307197B1 (en) 2025-11-01
CA3067247A1 (en) 2019-01-17
US20250163138A1 (en) 2025-05-22
AU2025200303A1 (en) 2025-02-13
MX2024005946A (es) 2024-06-11
JP2023120208A (ja) 2023-08-29
CO2020000369A2 (es) 2020-01-31
US11498960B2 (en) 2022-11-15
BR112019028269A2 (pt) 2020-07-14
IL271920B2 (en) 2024-03-01
US20230235033A1 (en) 2023-07-27
AU2018301412A9 (en) 2025-08-07
AU2018301412B2 (en) 2025-08-07
US20200399351A1 (en) 2020-12-24
IL307197A (en) 2023-11-01
JP7684803B2 (ja) 2025-05-28
WO2019014360A1 (en) 2019-01-17
RU2020102910A (ru) 2021-08-11
IL271920B1 (en) 2023-11-01
KR20200026264A (ko) 2020-03-10
RU2020102910A3 (cg-RX-API-DMAC7.html) 2021-12-02
JP2025118590A (ja) 2025-08-13
JP2020532285A (ja) 2020-11-12
CN111201246B (zh) 2023-10-27
AU2018301412A1 (en) 2020-01-30
IL324119A (en) 2025-12-01
KR20250099285A (ko) 2025-07-01
WO2019014360A8 (en) 2019-02-21
AU2025200313A1 (en) 2025-02-13
KR20250068795A (ko) 2025-05-16
US12221473B2 (en) 2025-02-11
KR102806328B1 (ko) 2025-05-14
EP3625265A1 (en) 2020-03-25
CN117327187A (zh) 2024-01-02
CN111201246A (zh) 2020-05-26
CN117327188A (zh) 2024-01-02

Similar Documents

Publication Publication Date Title
MX2024005946A (es) Polipeptidos que se unen al componente del complemento c5 o albumina serica y proteinas de fusion de los mismos.
PH12019500596A1 (en) Recombinant binding proteins and their use
AU2016240220B2 (en) Designed ankyrin repeat domains with binding specificity for serum albumin
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
HK1258509A1 (zh) Gitr激动剂
NZ748307A (en) Gdf15 fusion proteins and uses thereof
WO2015109124A3 (en) Immunomodulatory agents
EA201892774A1 (ru) Антитела
MY191944A (en) Binding proteins and methods of use thereof
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
PH12019500571A1 (en) Anti-pd-1 antibodies
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
MX2023001877A (es) Meganucleasas dise?adas especificas para secuencias de reconocimiento en el gen pcsk9.
MX390894B (es) Polipéptido de fusión anti-cáncer.
MY188183A (en) Antibodies to alpha-synuclein and uses thereof
PH12018501025A1 (en) Improved tnf binders
MX2024003743A (es) Inmunoglobulinas de union a agrecano.
WO2016172551A3 (en) Methods of identifying bacteria comprising binding polypeptides
MX2015000754A (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
EA201591898A1 (ru) Антитела, направленные на m-csf
WO2016040767A3 (en) Chrdl-1 epitopes and antibodies